Compare ERII & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ERII | PHVS |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 740.3M | 1.7B |
| IPO Year | 2008 | 2021 |
| Metric | ERII | PHVS |
|---|---|---|
| Price | $14.18 | $25.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $16.50 | ★ $39.44 |
| AVG Volume (30 Days) | 478.9K | ★ 532.0K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.56 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $135,191,000.00 | N/A |
| Revenue This Year | $5.93 | N/A |
| Revenue Next Year | $8.97 | N/A |
| P/E Ratio | $39.45 | ★ N/A |
| Revenue Growth | ★ 0.10 | N/A |
| 52 Week Low | $10.86 | $11.51 |
| 52 Week High | $18.32 | $29.80 |
| Indicator | ERII | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 41.68 | 54.34 |
| Support Level | $14.11 | $23.79 |
| Resistance Level | $14.75 | $25.44 |
| Average True Range (ATR) | 0.36 | 1.91 |
| MACD | 0.02 | -0.17 |
| Stochastic Oscillator | 2.06 | 41.22 |
Energy Recovery Inc is an engineering-driven technology company. It is engaged in engineering, designing, manufacturing and supplying solutions that make industrial processes more efficient and sustainable. The company operates in three segments, Water, Emerging Technologies and Corporate. It offers energy recovery devices (ERDs) and pumps as well as related products and services to the reverse osmosis desalination market. The company derives a majority of the revenue from the Water segment. Geographically, the company operates in the U.S. and other international countries.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.